Abiopharma

News list

MUIR GLENN P 🟡 adjusted position in 0 shares (1 derivative) of Cytek Biosciences, Inc. (CTKB) Transaction Date: Aug 18, 2026 | Filing ID: 000007

Full text

News bot Aug. 20, 2026, 8:31 p.m.
🔍 MUIR GLENN P (Executive)

Company: Cytek Biosciences, Inc. (CTKB)

Report Date: 2026-08-18
Transaction Summary:
- Total transactions: 2
- Derivative instruments: 1
- Holdings reported: 0
- Total shares acquired: 3,086
- Total shares sold: 3,086
Detailed Transactions and Holdings:
- Acquired 3,086 shares of Common Stock (Direct)
  Date: 2026-08-18 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,086.00 | transaction_form_type: 4 | Footnotes: F1
- Sold 3,086 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-18 | Code: M | equity_swap_involved: 0 | shares_owned_after: 52,469.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
Footnotes:
- F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
- F2: The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2026; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting on May 18, 2027 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2027 and each August 18 thereafter.